Fibrosis is estimated to contribute to over 40% of deaths in the developed world. Solid organ fibrosis is a component of numerous disease states, including idiopathic pulmonary fibrosis, non-alcoholic steatohepatitis, and chronic kidney disease.
Fibrotic conditions vary with respect to prevalence (ranging from orphan diseases to those affecting millions), etiology, morbidity, and mortality. The vast majority, however, are characterized by a lack of approved therapies for patients suffering from a chronic, progressive, and often life-threatening disease. Indalo’s goal is to bring safe and effective anti-fibrotic therapies to market to address these urgent unmet medical needs.